Article Details

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor

Retrieved on: 2021-05-04 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor. View article details on HISWAI: https://www.prnewswire.com/news-releases/vivace-therapeutics-announces-dosing-of-first-cohort-of-patients-with-its-first-in-class-tead-inhibitor-301283520.html

Excerpt

... including Canaan Partners, WuXi Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer Capital and RA Capital Mangement.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up